David Mauro

Biography

David brings over 15 years’ experience in oncology drug development to Checkmate, where he is responsible for the Company’s clinical development. He was most recently Chief Medical Officer at Advaxis where he oversaw the development of Advaxis’ Listeria-based immunotherapy platform technology. David has previously held senior level positions of increasing responsibility at Merck & Co. and Bristol Myers- Squibb Company, where he was involved in various aspects of oversight and implementation of cancer immunotherapy clinical development, translational science, and life cycle management for multiple small and large molecule programs. David participated in multiple successful regulatory filings including Erbitux® (cetuximab), Sprycel® (dasatinib), and Sylatron® (peginterferon alfa-2b). He received his Bachelor of Science in Biochemistry from Cornell University, his medical degree and his doctorate in pharmacology from Temple University School of Medicine, and completed his residency training at the National Cancer Institute.  

Research Interest

He was involved in various aspects of oversight and implementation of cancer immunotherapy clinical development, translational science, and life cycle management for multiple small and large molecule programs.